Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma

Malte Rieken, Stephen A. Boorjian, Luis A. Kluth, Umberto Capitanio, Alberto Briganti, R. Houston Thompson, Bradley C. Leibovich, Laura Maria Krabbe, Vitaly Margulis, Jay D. Raman, Mikhail Regelman, Pierre I. Karakiewicz, Morgan Rouprêt, Mohammad Abufaraj, Beat Foerster, Mithat Gönen, Shahrokh F. Shariat

Research output: Contribution to journalArticle

Abstract

Objectives: To develop and externally validate a model that quantifies the likelihood that a pathologically node-negative patient with clear cell renal cell carcinoma (cRCC) has, indeed, no lymph node metastasis (LNM). Patients and methods: Data from 1389 patients treated with radical nephrectomy (RN) and lymph node dissection (LND) were analyzed. For external validation, we used data from 2270 patients in the Surveillance, Epidemiology and End Results (SEER) database. We estimated the sensitivity of pathologic nodal staging using a beta-binomial model and developed a pathological nodal staging score (pNSS), which represents the probability that a patient is correctly staged as node negative as a function of the number of examined lymph nodes (LNs). Results: The mean and median number of LNs removed were 7.0 and 5.0 (standard deviation, SD 6.6; interquartile range, IQR 7.0) in the development cohort and 5.6 and 2.0 (SD 8.6, IQR 5.0) in the validation cohort, respectively. The probability of missing a positive LN decreased with increasing number of LNs examined. In both the validation and the development cohort, the number of LNs needed for correctly staging a patient as node negative increased with higher pathological tumor stage and Fuhrman grade. Conclusions: The number of examined LNs needed for adequate nodal staging in cRCC depends on pathological tumor stage and Fuhrman grade. We developed here and then externally validated a pNSS, which could help to refine patient counseling, decision-making regarding risk-stratified surveillance regimens and inclusion criteria for clinical trials of adjuvant therapy.

Original languageEnglish
Pages (from-to)1631-1637
Number of pages7
JournalWorld Journal of Urology
Volume37
Issue number8
DOIs
Publication statusPublished - Aug 1 2019

Keywords

  • Clear cell renal cell carcinoma
  • Lymph node dissection
  • Lymph node metastasis
  • Radical nephrectomy
  • SEER
  • Validation

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Rieken, M., Boorjian, S. A., Kluth, L. A., Capitanio, U., Briganti, A., Thompson, R. H., Leibovich, B. C., Krabbe, L. M., Margulis, V., Raman, J. D., Regelman, M., Karakiewicz, P. I., Rouprêt, M., Abufaraj, M., Foerster, B., Gönen, M., & Shariat, S. F. (2019). Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. World Journal of Urology, 37(8), 1631-1637. https://doi.org/10.1007/s00345-018-2555-5